E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Unlike what happens with other respiratory viruses, in a significant proportion of patients who have suffered from the disease, general and multi-organ symptoms may persist for months, which has been called long COVID |
A diferencia de lo que ocurre con otros virus respiratorios, en una proporción significativa de los pacientes que han sufrido la enfermedad pueden persistir síntomas generales y multiorgánicos durante meses, lo que se ha denominado COVID prolongado o persistente |
|
E.1.1.1 | Medical condition in easily understood language |
Some symptoms of COVID19 can continue for months after the acute phase of the infection. |
Algunos síntomas de la COVID19 pueden continuar meses después de haber superado la fase aguda de la infección. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of the COMIRNATY vaccine on the frequency and intensity of symptoms that persist three months after the acute phase of COVID. |
Evaluar el efecto de la vacuna COMIRNATY sobre la frecuencia e intensidad de la sintomatología que persiste tres meses después de la fase aguda de la COVID. |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the effect of the COMIRNATY vaccine on the frequency and intensity of the different general and organic symptoms that persist three months after the acute phase of COVID. -To evaluate the effect of the COMIRNATY vaccine on the quality of life of people with long COVID. -To evaluate the safety of the COMIRNATY vaccine in people with long COVID. |
-Evaluar el efecto de la vacuna COMIRNATY sobre la frecuencia e intensidad de los diferentes síntomas generales y orgánicos que persisten tres meses después de la fase aguda de la COVID. -Evaluar el efecto de la vacuna COMIRNATY sobre la calidad de vida de las personas con COVID persistente. -Evaluar la seguridad de la vacuna COMIRNATY en personas con COVID persistente. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Adults (≥18 years) admitted for COVID-19 who continue with moderate or severe symptoms collected in the “COVID-19 Symptom Questionnaire” three months after hospital discharge and who sign the informed consent |
Personas adultas (≥18 años) ingresadas por COVID-19 que continúan con síntomas moderados o intensos recogidos en el “Cuestionario de síntomas COVID-19” tres meses después del alta hospitalaria y que firmen el consentimiento informado. |
|
E.4 | Principal exclusion criteria |
-Patients who have received any dose of any of the COVID-19 vaccines. -Contraindication for the COMIRNATY vaccine according to the technical data sheet. -Women who are pregnant or intend to become pregnant during the next three months after the administration of the vaccine. |
-Pacientes que hayan recibido alguna dosis de cualquiera de las vacunas contra la COVID-19. -Contraindicación para la vacuna COMIRNATY según ficha técnica. -Mujeres embarazadas o que pretendan quedarse embarazadas durante los siguientes tres meses tras la administración de la vacuna. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in the global score of the “COVID-19 Symptom Questionnaire” at week 12 after the administration of the second dose of COMIRNATY vaccine |
Cambio en la puntuación global del “Cuestionario de síntomas COVID-19” a la semana 12 de la administración de la segunda dosis de la vacuna COMIRNATY. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary end point will be analyzed 12 weeks after the administration of the second dose of the vaccine that is administered 21 (+/- 2) days after the first one. |
El end point primario se determinará 12 semanas después de la administración de la segunda dosis de la vacuna que se administra 21 (+/-2) días después de la primera dosis. |
|
E.5.2 | Secondary end point(s) |
-Change in the global score of the “COVID-19 Symptom Questionnaire” at week 24 and 48 after the administration of the second dose of COMIRNATY vaccine. -Change in the score of each one of the “symptomatic areas” of the “COVID-19 Symptom Questionnaire” at weeks 12, 24 and 48 after the administration of the second dose of COMIRNATY vaccine: general, respiratory / thoracic symptoms, digestive, otorhinolaryngological and neuropsychiatric. -Change in the score of each of the symptoms in the “COVID-19 Symptom Questionnaire” at weeks 12, 24 and 48 after the administration of the second dose of COMIRNATY vaccine. -Change in the score on the anxiety, depression and quality of sleep scales at week 12, 24 and 48 after the administration of the second dose of the COMIRNATY vaccine. -Change in the score in the WHOQOL-Bref quality of life questionnaire at weeks 12, 24 and 48 after the administration of the second dose of the COMIRNATY vaccine. -Proportion of symptoms that improve, do not change, or worsen at weeks 12, 24, and 48 after the second dose of COMIRNATY vaccine is administered. -Proportion of patients who develop clinical and laboratory adverse events at weeks 12, 24 and 48 after the administration of the second dose of COMIRNATY vaccine. |
-Cambio en la puntuación global del “Cuestionario de síntomas COVID-19” a la semana 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY. -Cambio en la puntuación de cada una de las “esferas sintomáticas” del “Cuestionario de síntomas COVID-19” a las semanas 12, 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY: síntomas generales, respiratorios/torácicos, digestivos, otorrinolaringológicos y neuropsiquiátricos. -Cambio en la puntuación de cada uno de los síntomas en el “Cuestionario de síntomas COVID-19” a las semanas 12, 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY. -Cambio en la puntuación en las escalas de ansiedad, depresión y calidad del sueño a la semana 12, 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY. -Cambio en la puntuación en el cuestionario de calidad de vida WHOQOL-Bref a la semana 12, 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY. -Proporción de los síntomas que mejoran, no cambian o empeoran a la semana 12, 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY. -Proporción de pacientes que desarrollan acontecimientos adversos clínicos y de laboratorio a la semana 12, 24 y 48 de la administración de la segunda dosis de la vacuna COMIRNATY. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The secondary end points will be analyzed 12, 24 or 48 weeks after the administration of the second dose of the vaccine that is administered 21 (+/- 2) days after the first one. |
Los end point secundarios se determinarán 12, 24 o 48 semanas después de la administración de la segunda dosis de la vacuna que se administra 21 (+/-2) días después de la primera dosis. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |